Drug Database
ON

ondansetron (Zuplenz / ondansetron OFDS)

✓ Approved

Galena Biopharma, Inc. · HTR3A · 小分子

什么是 ondansetron?

ondansetron 是一种小分子,由Galena Biopharma, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Zuplenz, ondansetron OFDS
公司Galena Biopharma, Inc.
药物类别小分子
分子靶点HTR3A
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

ondansetron 作用于 1 个分子靶点:

HTR3A5-hydroxytryptamine receptor 3A (5-HT3R, 5-HT-3)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

相关研究文献

PubMedNursing2026-11-16

Implementation of a spinal-induced hypotension management bundle for elective cesarean delivery.

Meitzner Olivia O, Klink Meghan M, McDaniel Katherine K, Wofford Kenneth K et al.

Spinal-induced hypotension (SIH) remains the most common complication associated with spinal anesthesia for cesarean delivery and may compromise maternal hemodynamic stability and uteroplacental perfusion. Evidence supports prophylactic vasopressor therapy, serotonin receptor antagonists, and optimized fluid management; however, these strategies are inconsistently applied in clinical practice. This quality improvement (QI) project evaluated the effect of a standardized SIH management bundle (SIHMB) on maternal hemodynamic outcomes. A prospective QI initiative was conducted in the obstetric operating suites of an academic medical center with a Level II trauma facility. Adult parturients undergoing elective cesarean delivery under spinal anesthesia were included. The intervention bundle consisted of intravenous ondansetron 8 mg administered 5 to 10 minutes prior to spinal anesthesia, crystalloid co-loading with 1 L of fluid during spinal placement, and prophylactic phenylephrine infusion initiated at 0.5 mcg/kg per minute. Data were collected during 12-week preimplementation and postimplementation periods. Primary outcomes included incidence and severity of hypotension. Secondary outcomes included rescue vasopressor use, antiemetic administration, and bundle adherence. This QI project was reported in accordance with the SQUIRE 2.0 guidelines for reporting QI initiatives. A total of 242 patients were included (103 preimplementation, 139 postimplementation). Implementation of the SIHMB significantly reduced the incidence of hypotension from 46% to 32% (P = .024). Mean lowest systolic and diastolic blood pressures increased significantly following implementation. Rescue vasopressor administration decreased from 72% to 49% (P < .001). Utilization of prophylactic phenylephrine infusion increased from 32% to 62%. Implementation of a standardized hemodynamic management bundle significantly improved maternal hemodynamic stability during cesarean delivery. Standardizing prophylactic strategies for SIH may enhance obstetric anesthesia safety and reduce reliance on reactive vasopressor therapy.

PMID 43038418
阅读全文 →
PubMedMedical science monitor : international medical journal of experimental and clinical research2026-11-10

Oliceridine vs Sufentanil Combined With Ondansetron for Postoperative Nausea and Vomiting and QTc Interval in Hysteroscopic Surgery: A Prospective Randomized Controlled Study.

Guo Zhijia Z, Wu Yanan Y, Sang Yuqian Y

BACKGROUND Postoperative nausea and vomiting (PONV) is common after hysteroscopic surgery, and opioid use can raise concerns regarding cardiac safety. This prospective study aimed to compare the effects of oliceridine plus ondansetron versus sufentanil plus ondansetron on 24-hour PONV incidence and perioperative changes in the corrected QT interval (QTc) in patients undergoing non-intubated hysteroscopy under general anesthesia. MATERIAL AND METHODS In this randomized, double-blind, controlled study, 62 patients undergoing hysteroscopic surgery under general anesthesia were analyzed. Patients received propofol 2 mg/kg with either oliceridine 0.039 mg/kg plus ondansetron 4 mg (O group) or sufentanil 0.1 μg/kg plus ondansetron 4 mg (S group). The primary endpoint was 24-hour PONV. Secondary endpoints included emergence time, post-anesthesia care unit (PACU) pain scores, and change in QTc from baseline (ΔQTc) measured by 5-lead electrocardiography at predefined time points. RESULTS PONV incidence within 24 h did not differ significantly between groups (0% vs 3.2%, P>0.05). Time to anesthesia emergence was comparable between groups (P=0.960). Numerical rating scale scores at PACU discharge were also comparable (P=0.186). Repeated-measures ANOVA showed a significant time effect for ΔQTc (P=0.001), but no significant group effect (P=0.076) or group×time interaction (P=0.171). CONCLUSIONS Oliceridine plus ondansetron did not significantly reduce 24-hour PONV compared with sufentanil plus ondansetron, and this finding should be interpreted cautiously because of limited statistical power. Perioperative ΔQTc changes were minimal and similar between groups, with no clinically significant QTc prolongation.

PMID 43004669
阅读全文 →
PubMedMolecular neurobiology2026-11-10

Retraction Note to: Repeated Forced Swim Exacerbates Methamphetamine-Induced Neurotoxicity: Neuroprotective Effects of Nanowired Delivery of 5-HT3-Receptor Antagonist Ondansetron.

Lafuente José Vicente JV, Sharma Aruna A, Muresanu Dafin F DF, Ozkizilcik Asya A et al.

PMID 43007577
阅读全文 →
PubMedWideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques2026-11-06

Risk factors for postoperative nausea and vomiting after sleeve gastrectomy and the impact of intraoperative ondansetron: a retrospective cohort study.

Dobruchowska-Kęsikowska Eliza E, Wityk Mateusz M, Mysiorska Dominika D, Młyńska Julia J et al.

Postoperative nausea and vomiting (PONV) remain common adverse postoperative events after sleeve gastrectomy (SG), and they may negatively affect patient recovery. The aim of this study was to identify risk factors for PONV after SG and to evaluate the impact of intraoperative ondansetron administration on both the occurrence and severity of PONV. A retrospective analysis of patients who underwent primary SG between 2024 and 2025 in a single bariatric center was conducted. Since PONV episodes were not recorded directly, the symptoms were assessed indirectly based on antiemetic consumption. Any PONV was defined as administration of at least 8 mg of ondansetron within 24 hours after surgery, whereas severe PONV was defined as a requirement for 16 mg of ondansetron or more with or without additional antiemetic agents. A total of 463 patients were included. Any PONV occurred in 195 patients (42.1%), while severe PONV was observed in 57 individuals (12.3%). Male sex (odds ratio [OR], 0.36; 95% CI, 0.22-0.61; P <0.001), older age (OR, 0.97; 95% CI, 0.95-0.99; P = 0.01), elevated body mass index (OR, 0.96; 95% CI, 0.93-1; P = 0.03), hypertension (OR, 0.53; 95% CI, 0.33-0.83; P = 0.006), and intraoperative ondansetron administration (OR, 0.38; 95% CI, 0.24-0.58; P <0.001) were independently associated with a lower risk of any PONV. Male sex was an independent protective factor against severe PONV (OR, 0.11; 95% CI, 0.03-0.48; P = 0.003). Intraoperative ondansetron administration was associated with a lower risk of PONV after SG. Male sex was the only independent protective factor against severe PONV, while ondansetron showed no significant effect on the occurrence of severe symptoms.

PMID 42992072
阅读全文 →
PubMedAcademic emergency medicine : official journal of the Society for Academic Emergency Medicine2026-11-05

Comparative Effectiveness of Haloperidol, Droperidol, and Ondansetron for Cannabinoid Hyperemesis Syndrome in the Emergency Department.

O'Brien Joseph J, Patel Mayher M, Brown Joseph J, Tucker Ryan R et al.

Cannabinoid hyperemesis syndrome (CHS) is an increasingly frequent emergency department (ED) presentation. Although ondansetron is commonly used, emerging evidence suggests haloperidol and droperidol may provide more effective symptom control. Robust comparative effectiveness data, particularly regarding short-term ED recidivism, remain limited. We conducted a multicenter retrospective cohort study using the TriNetX Research Network from 2014 to 2024. Adults presenting to the ED with vomiting-related and cannabis-related ICD-10 diagnoses who received haloperidol, droperidol, or ondansetron during the index encounter were included. Patients with alternative causes of vomiting or major confounding conditions were excluded. Propensity-score matching was performed for three pairwise comparisons: haloperidol versus ondansetron, droperidol versus ondansetron, and droperidol versus haloperidol. The primary outcome was 72-h ED recidivism. Secondary outcomes included 72-h hospital admission, 7-day ED recidivism, and coded adverse events. Multivariable Cox proportional hazards modeling evaluated independent predictors of 72-h ED recidivism. After matching, haloperidol was associated with lower 72-h ED recidivism compared with ondansetron (8.2% vs. 15.1%; OR 0.50, 95% CI 0.41-0.62; p < 0.0001). Droperidol was also associated with lower 72-h ED recidivism compared with ondansetron (7.4% vs. 14.0%; OR 0.49, 95% CI 0.32-0.76; p = 0.0014). Droperidol and haloperidol did not differ significantly in 72-h ED recidivism (7.5% vs. 9.8%; OR 0.75, 95% CI 0.47-1.20; p = 0.23). In the multivariable model, haloperidol (HR 0.62, 95% CI 0.49-0.79) and droperidol (HR 0.68, 95% CI 0.56-0.83) were independently associated with lower return risk, whereas ondansetron was not. Coded adverse events were rare across all groups. In this large multicenter cohort, haloperidol and droperidol were associated with lower short-term ED recidivism than ondansetron among adults meeting a suspected CHS phenotype. These findings support prospective studies evaluating haloperidol and droperidol for ED management of CHS, including optimal dosing, route, medication sequencing, discharge treatment, and safety monitoring.

PMID 42983225
阅读全文 →
PubMedSurgery2026-11-05

Effectiveness of 5-hydroxytryptamine 3 receptor antagonists in the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: A systematic review and network meta-analysis of randomized controlled trials.

Yuan Liyun L, Zeng Wenjing W, Ren Peng P, Yu Haichuan H

Numerous 5-hydroxytryptamine 3 receptor antagonists are available to prevent postoperative nausea and vomiting after laparoscopic cholecystectomy, but relevant comparative data are limited. This study aimed to compare various 5-hydroxytryptamine 3 receptor antagonists in preventing postoperative nausea and vomiting after laparoscopic cholecystectomy via systematic review and network meta-analysis. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We systematically searched for articles in PubMed, Cochrane, Embase, and WOS up to August 2025. The quality of included studies was assessed utilizing the National Institutes of Health Study Quality Assessment Tools. Network meta-analysis was performed to evaluate the effectiveness (risk ratio) of various 5-hydroxytryptamine 3 receptor antagonists, different doses, and usage time of various 5-hydroxytryptamine 3 receptor antagonists in postoperative nausea and vomiting prevention after laparoscopic cholecystectomy. To avoid anomalies in data analysis caused by the absence of postoperative nausea and vomiting, no postoperative nausea and vomiting was analyzed. A total of 21 studies (n = 2,033 patients) were included. The results revealed that compared with placebo, ramosetron (risk ratio, 2.60) and palonosetron (risk ratio, 2.50) pronouncedly prevented postoperative nausea and vomiting; tropisetron (risk ratio, 0.23), ramosetron (risk ratio, 0.25), and palonosetron (risk ratio, 0.27) significantly prevented nausea; ramosetron (risk ratio, 0.10) markedly prevented vomiting. Ramosetron (risk ratio, 0.43) demonstrated greater efficacy than ondansetron in preventing retching. In subgroup analyses, ondansetron 8 mg outperformed ondansetron 4 mg in preventing nausea, vomiting, and retching. The administration of ondansetron, ramosetron, palonosetron, and granisetron at the end of the operation outperformed preoperative administration in postoperative nausea and vomiting. Among the 5-hydroxytryptamine 3 receptor antagonists, palonosetron and ramosetron show better efficacy in preventing postoperative nausea and vomiting after laparoscopic cholecystectomy. Subgroup analyses show that 8 mg of ondansetron outperforms 4 mg of ondansetron. Administration of drugs at the end of the operation outperforms preoperative administration.

PMID 42987665
阅读全文 →

注册免费账户还可查看另外 5438 篇文献

免费注册查看全部文献 →

了解更多ondansetron